Breaking News
October 17, 2018 - Modeling Non-Numerical Data in Systems Biology
October 17, 2018 - Research aims to address health disparities in African-American men
October 17, 2018 - Human and cattle decoys trap outdoor-biting mosquitoes in malaria endemic regions
October 17, 2018 - High Circulating Prolactin Level Inversely Linked to T2DM Risk
October 17, 2018 - Study finds gene variant predisposes people to both Type 2 diabetes and low body weight
October 17, 2018 - Network of doctors identify the cause of 31 new conditions
October 17, 2018 - Notable improvement in brain cancer survival among younger patients but not much for elderly
October 17, 2018 - Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma
October 17, 2018 - Costs of Medicare Diabetes Prevention Program may be higher than expected reimbursement
October 17, 2018 - Misuse of prescription opioids or benzodiazepines associated with suicidal thoughts
October 17, 2018 - New research seeks to address sex disparities in women’s health
October 17, 2018 - C-Section Rates Have Nearly Doubled Since 2000: Study
October 17, 2018 - Talking to Your Kids About STDs
October 17, 2018 - New classification of periodontal and peri-implant diseases and conditions
October 17, 2018 - Herbert D. Kleber, Pioneer in Addiction Treatment, Dies at 84
October 17, 2018 - Health effects of smoke-filled atmosphere
October 17, 2018 - Down syndrome may hold important clues to onset of Alzheimer’s disease
October 17, 2018 - A special report on US’ aging societies
October 17, 2018 - Birth mode may have acute effects on neurodevelopment, study suggests
October 17, 2018 - Global health innovation system fails to deliver affordable treatments to patients, says report
October 17, 2018 - Simple, inexpensive test quickly detects antibiotic-resistant ‘superbugs’
October 17, 2018 - New drugs could reduce risk of heart disease when added to statins
October 17, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum
October 17, 2018 - HVP vaccination not linked with rise in teen risky sex
October 17, 2018 - Potential ‘early warning markers’ for sepsis discovered
October 17, 2018 - Who knew? Life begins (again) at 65
October 17, 2018 - Application of blood pressure guidelines ups treatment
October 17, 2018 - Stanford researchers find that small molecule may help treat enzyme deficiency
October 17, 2018 - Speed Cameras Save Money and Lives in New York City
October 17, 2018 - Men who conform to ‘the man box’ more likely to consider suicide and violence
October 17, 2018 - Researchers aim to create more authentic organoids for drug testing, transplantation
October 16, 2018 - New blood test for pediatric brain tumor patients offers safer approach than surgical biopsies
October 16, 2018 - Age-related estrogen increase may be the culprit behind inguinal hernias in men
October 16, 2018 - Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
October 16, 2018 - Researchers uncover new role of TIP60 protein in controlling tumour formation
October 16, 2018 - Behind the scenes of a lifesaving heart surgery
October 16, 2018 - ‘To See the Suffering’
October 16, 2018 - Drinking concentrated rosemary extract can boost memory by up to 15%, shows research
October 16, 2018 - Medicare Advantage riding high as new insurers flock to sell to seniors
October 16, 2018 - NHS tackles prescription fraud to save millions
October 16, 2018 - New molecular switch may help develop sophisticated photomedications
October 16, 2018 - Improving access to behavioral health screenings for pregnant and postpartum women
October 16, 2018 - Health Highlights: Oct. 12, 2018
October 16, 2018 - Study holds promise for new pediatric brain tumor treatment
October 16, 2018 - Patient advocate uses MRI scans to create art and spark conversations about life with illness
October 16, 2018 - Fish oil based diets may suppress growth and spread of breast cancer cells
October 16, 2018 - Number of VHA facilities offering acupuncture has increased rapidly
October 16, 2018 - Influential Leapfrog Group jumps in to rate 5,600 surgery centers
October 16, 2018 - HIV-infected infants more likely to acquire congenital cytomegalovirus infection
October 16, 2018 - Study pinpoints new marker that can predict Crohn’s disease subtype
October 16, 2018 - Simple procedure could be efficacious intervention for failed back surgery
October 16, 2018 - New research identifies modifiable dementia risk factor in elderly people
October 16, 2018 - Zebrafish study uncovers molecular ‘brake’ that helps control eye lens development
October 16, 2018 - Overlapping copy number variations underlie autism and schizophrenia in Japanese patients
October 16, 2018 - Early menopause and diabetes may reduce life expectancy
October 16, 2018 - Majority of Americans’ ancestry can be traced through existing DNA databases
October 16, 2018 - Patients coerced into mental health care less likely to perceive treatment as effective
October 16, 2018 - Healthy elders can consume walnuts without having negative impact on weight gain, finds study
October 16, 2018 - Interactive robot helps older people exercise and detects underlying health problems
October 16, 2018 - What you need to know about autism spectrum disorder
October 16, 2018 - Antidepressants can be used to treat Alzheimer’s disease
October 16, 2018 - Study uncovers important role of PRMT1 in dilated cardiomyopathy
October 16, 2018 - Nutritional quality of breakfast linked to cardiovascular and metabolic risk factors in children
October 16, 2018 - Study uses novel approach to investigate genetic origins of mental illnesses
October 16, 2018 - Scientists develop dual anthrax-plague vaccine
October 16, 2018 - Poor Outcomes for Hispanic Infants With Congenital Heart Dz
October 16, 2018 - Global study finds youngest in class more likely to be diagnosed with ADHD
October 16, 2018 - Researchers sequence two selfish genes in the fungus Neurospora intermedia
October 16, 2018 - Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis
October 16, 2018 - Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration
October 16, 2018 - Researchers create open access database on healthy immunity
October 16, 2018 - Rice University chemist wins big award to study small surfaces
October 16, 2018 - Study finds 43% drop in stroke rate
October 16, 2018 - Researchers identify basic relationships of cell cycle and cellular senescence in the placenta
October 16, 2018 - UA professor receives NSF grant to develop antifouling materials for medical implants
October 16, 2018 - Obesity Doubles Odds for Colon Cancer in Younger Women
October 16, 2018 - Adults with ADHD not constrained in creativity
October 16, 2018 - Raising visibility for people and students with chronic illness and disability
October 16, 2018 - Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis
October 16, 2018 - Only 59% of young adults undergoing surgery are fluid responsive
‘Cutting edge’ CAR T cell immunotherapy approved in England. But is the NHS ready?

‘Cutting edge’ CAR T cell immunotherapy approved in England. But is the NHS ready?

image_pdfDownload PDFimage_print
Credit: CC0 Public Domain

Today, a new blood cancer treatment was approved for use on the NHS in England. And in early September, NHS England announced another, similar treatment will be available to some children and young people with a different type of blood cancer.

As with any new drug approval, these announcements are great news for the patients who may benefit. But these are no ordinary drugs.

The two treatments – called axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) respectively – have attracted attention because of the ground-breaking way in which they’re made and work.

This makes their approval a fascinating live case study for an NHS that’s attempting to position itself as a world-leader in cancer treatment.

What is CAR T cell therapy?

Yescarta and Kymriah are two of a new line of immune-boosting treatments called CAR T cell therapies.

They involve extracting specialised immune cells, called T cells, from a patient’s blood and altering them in the lab so they recognise and fight cancer cells. The modified T cells are multiplied a thousand-fold in the lab and then put back into the patient’s bloodstream.

The results from small trials have been promising, as the cellular engineering turns patients’ own immune systems into precise anti-cancer weapons. And unlike standard chemotherapy, the treatment only has to be given once.

CAR T cells are “the first truly personalised therapy, because the cells come from the patient,” says Professor Karl Peggs, a Cancer Research UK-funded immunotherapy expert. He says this makes it a game-changer “in the small niche in which it is being licensed and used”.

In other words, while the technology is exciting, at the moment it will only reach a relatively small number of people, and that’s unlikely to change any time soon.

In fact, Peggs cautions against overplaying the potential for CAR T to turn blood cancer treatment on its head. For childhood acute lymphoblastic leukaemia – one of the cancer types CAR T can now be used in – he says only a tiny fraction of patients will benefit from the new treatment because “most patients are cured with conventional therapy”.

But for the few patients in whom chemotherapy hasn’t worked, the approval of CAR T offers a vital new option.

How effective is CAR T?

Impressive results have been reported in clinical trials for some types of blood cancer where there are few other treatment options available. In one trial, around 8 in 10 patients saw their disease respond to the treatment, and for around half of those patients their cancer hadn’t come back a year later.

But, while the treatment has shown great promise, it doesn’t work for everyone. According to Peggs, it’s unknown why only some patients’ cancers respond initially, and why others see their cancer come back later while some remain disease free.

More research will help answer these questions, and the terms of the treatments’ approval on the NHS state that data on their effectiveness can be collected along the way. This, again, is positive news.

The potency of unleashing the immune system also brings with it the risk of serious side effects that need expert care. In one clinical trial testing Yescarta, 94 percent of patients experienced a side effect called cytokine release syndrome, and 1 in 7 of them needed treatment in intensive care.

Despite the challenges, these treatments have attracted a lot of interest. The head of the NHS in England, Simon Stevens, has described CAR T therapy as “cutting edge” and “one of the most innovative treatments ever offered on the NHS”.

But the complexity of these treatments means they pose more of a challenge to the NHS than most new drugs.

Is the NHS ready for CAR T therapies?

“In many ways, this treatment is more akin to a stem cell transplant than traditional chemotherapy,” says Peggs. NHS England has selected hospitals where staff have experience of procedures like stem cell or bone marrow transplants as the first locations to offer the treatment. The NHS is already in a strong position, as it has world-class facilities for carrying out these procedures.

But those hospitals will also have to plan for patients’ supportive care. To help monitor side effects, people having CAR T therapy will have to stay in hospital afterwards, and be within easy travelling distance for several weeks after they leave.

This means the treatment will initially only be given to a few patients at a time across England, in a limited number of hospitals, to make sure the NHS can look after them properly.

It’s not yet clear whether patients in Wales and Northern Ireland will need to travel to hospitals in England to be treated. And in Scotland, on top of this uncertainty, these treatments would also have to be separately approved by the Scottish Medicines Consortium (SMC) before they can receive NHS funding. The SMC is due to decide on Yescarta in November, and on Kymriah in early 2019.

Complexity aside, one of the major debates surrounding CAR T cell therapies has been their cost. The treatments are expensive, at around £280,000 per patient, though the NHS has negotiated significant discounts for both Yescarta and Kymriah. Both the NHS and the companies that develop these treatments, Gilead and Novartis, deserve huge credit for agreeing deals for these drugs.

CAR T therapy is an extreme example of a general trend for the newest cancer drugs, which are more personalised and complex, but pricier as a result. This trend makes it vital the NHS explores new ways of paying for cancer drugs, which could make it easier to approve exciting new treatments in future so that patients can access them more quickly.

We’re working with partners in Greater Manchester to explore one approach called outcomes-based pricing, where the NHS pays a different price for the drug, based on the benefits it gives patients.

What does this all mean for patients and the NHS?

The NHS approvals of Kymriah and Yescarta are a huge leap forward for those patients in England with the very specific blood cancers they are approved to treat.

But even for these patients, there are still unanswered questions about the drugs’ long-term effectiveness, which patients are most likely to respond, and how to manage and reduce side effects. We, and others, are hoping to answer these questions through research.

The NHS can rightly be proud that a small number of patients in England will be the first in Europe to have routine access to this highly complex technology. But the challenges presented by exciting new treatments like CAR T won’t go away. Today’s good news should be just the start, not the end, of the NHS’s preparations for this shift.


Explore further:
Engineered cell therapy rejected for aggressive adult lymphoma on NHS in England

Provided by:
Cancer Research UK

Tagged with:

About author

Related Articles